Cognition Therapeutics (CGTX) Accumulated Expenses (2020 - 2026)

Cognition Therapeutics (CGTX) has 7 years of Accumulated Expenses data on file, last reported at $1.7 million in Q1 2026.

• Quarterly Accumulated Expenses fell 78.02% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 78.02% YoY) and the FY2025 annual result came in at $9.9 million, up 74.87% from the prior year.
• Accumulated Expenses declined to $1.7 million in Q1 2026 per CGTX's latest filing, from $9.9 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $9.9 million in Q4 2025 and bottomed at $748000.0 in Q2 2022.
• The 5-year median for Accumulated Expenses is $2.3 million (2022), against an average of $3.7 million.
• The widest annual swing landed in 2024, when Accumulated Expenses surged 385.32%; it then plunged 78.02% in 2026.
• Tracing CGTX's Accumulated Expenses over 5 years: stood at $900000.0 in 2022, then increased by 29.44% to $1.2 million in 2023, then surged by 385.32% to $5.7 million in 2024, then soared by 74.87% to $9.9 million in 2025, then slumped by 82.87% to $1.7 million in 2026.
• Per Business Quant, the three latest CGTX Accumulated Expenses figures stand at $1.7 million (Q1 2026), $9.9 million (Q4 2025), and $2.5 million (Q3 2025).

Peer Comparison